References
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
- Pilkington GJ. Cancer stem cells in the mammalian central nervous system. Cell Prolif 2005; 38: 423-33.
- Baur M, Preusser M, Piribauer M, Elandt K, Hassler M, Hudec M. Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. Radiol Oncol 2010; 44: 113-20.
- Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
- Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005; 5: 899-904.
- Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nature Rev Cancer 2010; 10: 319-31.
- Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-9.
- Brabletz T, Jung A, Spaderna SW, Hlubek F, Kirchner T. Migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-9.
- Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 2009; 35: 403-8.
- Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
- Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat Clin Pract Neurol 2008; 4: 427-35.
- Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88: 808-15.
- Beier D, Hau P, Proeschold M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-5.
- Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122: 761-8.
- Prestegarden L, Svendsen A, Wang J, Sleire L, Skaftnesmo KO, Bjerkvig R, et al. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res 2010; 70: 4274-9.
- Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291: 113-35.
- Lah TT, Durán Alonso MB, Van Noorden CJ. Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 2006; 6: 257-79.
- Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007; 6: 60-4.
- Levicar N, Nutall RK. Lah TT. Proteases in brain tumour progression. Acta Neurochir 2003; 145: 825-38.
- Vranic A. Antigen expression on recurrent meningioma cells. Radiol Oncol 2010; 44: 107-12.
- Lah T, Obermajer N, Duran-Alonso MB, Kos J. Cysteine cathepsins and cystatins as cancer biomarkers. In: Edwards DR, editor. The cancer degradome: proteases and cancer biology. New York: Springer; 2008. p. 585-23.
- http://www.merops.ec.uk
- Strojnik T, Kavalar R, Trinkaus M, Lah TT. Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect Prev 2005; 29: 448-55.
- Colin C, Voutsinos-Porche B, Nanni I, Fina F, Metellus PH, Intagliata D, et al. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 2009; 118: 745-54.
- Gole B, Durán Alonso MB, Dolenc V, Lah TT. Post-translational regulation of cathepsin B, but not other cysteine cathepsins, contributes to increase glioblastoma cell invasion in vitro. Pathol Oncol Res 2009; 15: 711-23.
- Sivaparvathi M, Yamamoto M, Nicolson GL, Gokaslan ZL, Fuller GN, Liotta LA, et al. Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metastasis 1996; 14: 27-34.
- Lah TT, Strojnik T, Levicar N, Bervar A, Zajc I, Pilkington G, et al. Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors. Int J Biol Markers 2000; 15: 90-3.
- Levičar N, Dewey RA, Daley E, Bates TE, Davies D, Kos J, et al. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther 2003; 10: 141-51.
- Zajc I, Hreljac I, Lah T. Cathepsin L affects apoptosis of glioblastoma cells: a potential implication in the design of cancer therapeutics. Anticancer Res 2006; 26: 3357-64.
- Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M, et al. Cathepsin S expression: An independent prognostic factor in glioblastoma tumours-A pilot study. Int J Cancer 2006; 119: 854-60.
- Kos J, Lah TT. Cystatins in cancer. In: Žerovnik E, Kopitar-Jerala N (eds). Human Stefins and Cystatins. New York: Nova Science Publishers Inc; 2006. p. 152-65.
- Sakariassen PØ, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 2006; 103: 16466-71.
- Palmer TD, Schwartz PH, Taupin P, Kaspar B, Stein SA, Gage FH. Progenitor cells from human brain after death. Nature 2001; 411: 42-3.
- Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, et al. Differentiation therapy exerts antitumour effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715-28.
- Demuth T, Rennert JL, Hoelzinger DB, Reavie LB, Nakada M, Beaudry C, et al. Glioma cells on the run - the migratory transcriptome of 10 human glioma cell lines. BMC Genomics 2008; 9: 54.
- Campos B, Herold-Mende CC. Insight into the complex regulation of CD133 in glioma. Int J Cancer 2010; 128: 501-10.
- Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cell Dev 2009; 18: 1127-34.
- Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-9.
- Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 8205-12.
- Kong D-S, Kim MH, Park W-Y, Suh Y-L, Lee J-I, Park K, et al. The progression of gliomas is associated with cancer stem cell phenotype. Oncol Rep 2008; 19: 639-43.
- Strojnik T, Røsland GV, Sakariassen PO, Kavalar R, Lah Turnsek T. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 2007; 68: 133-43.
- Birgersdotter A, Sandberg R, Ernberg I. Gene expression perturbation in vitro-a growing case for three-dimensional (3D) culture systems. Semin Cancer Biol 2005; 15: 405-12.
- Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, Bauer H, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006; 118: 2182-9.
- Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH, et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008; 265: 124-34.
- Schmitt M, Jaenicke F, Graeff H. Protease, matrix degradation and tumourcell spread. Fibrinolysis 1992; 6: 1-17.
- Friedl P, Wolf K. Tumour cell invasion and migration. Diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.
- Zajc I, Bervar A, Lah Turnšek T. Cysteine cathepsins, stefins and extracellular matrix degradation during invasion of transformed human breast cell lines. Radiol Oncol 2006; 40: 259-71.
- Strojan P. Cysteine cathepsins and stefins in head and neck cancer: an update of clinical studies. Radiol Oncol 2008; 42: 69-81.
- Berquin LM, Sloane BF. Cathepsin B expression in human tumours. Adv Exp Med Biol 1996; 389: 281-94.
- Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, at al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005; 11: 206-13.